HSV Testing Market By Type (HSV-1, HSV-2, Others), By Test Type (Serological Tests, PCR Tests, Rapid Diagnostic Tests, Culture-Based Tests), By Sample Type (Blood, Serum, Swab Samples), By Applications (Routine Screening, Diagnosis of Active Infection, Prenatal Testing, Epidemiological Studies, Others), and By End-User (Hospitals and Clinics, Diagnostic Laboratories, At-Home Testing, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape the HSV Testing Market in the coming years?

The HSV Testing Market accounted for USD 619.80 Million in 2024 and USD 657.73 Million in 2025 is expected to reach USD 1191.30 Million by 2035, growing at a CAGR of around 6.12% between 2025 and 2035. The HSV Testing Market is centered on the diagnostic tools to diagnose herpes simplex virus (HSV) infections or herpes simplex virus-1 and herpes simplex virus-2. Most utilize the diagnostic tests to detect present viral infections and previous exposure to the organism, and they are essential in the management and prevention of the disease. Some of the testing methods that have been included in the market are polymerase chain reaction (PCR) tests, serological tests, rapid diagnostic tests, and culture-based methods.

Molecular advances have enhanced the accuracy and speed with which HSV testing occurs, enabling it to be used in clinical practice without many hurdles. The market serves both the healthcare facilities and the at-home testing solutions, which indicate the rising awareness concerning sexually transmitted infections. The interest in early detection and the advent of new testing kits is also broadening its location. Also, the capacity to integrate with digital health platforms and telemedicine is increasing access and convenience for the patient. The need to have consistent, prompt diagnosis to inform the course of action and limit expansion is a driver of the market.

What do industry experts say about the HSV Testing market trends?

“We all look for accurate and timely diagnosis options for HSV infections. Advanced testing technologies and at-home solutions make it easier for patients to access care quickly and conveniently.”

• Dr. Michael Andrews, Clinical Virologist & Director, Global Infectious Disease Diagnostics

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the HSV Testing market?

Is increasing awareness about sexually transmitted infections driving HSV test demand?

Raising awareness of sexually transmitted diseases (STDs) is a major driver in the HSV testing market. As people learn more about STIs, it is more likely that they will want to be tested, and therefore, diagnostic services are in increased demand. This increased awareness is motivated by the efforts of national and global health agencies in creating awareness about the need to prevent STIs and early detection of the same. An example is that the World Health Organization (WHO) has reported that in 2020, a total of 374 million new infections were estimated to have occurred in people aged 15-49 years with one of four curable STIs: chlamydia, gonorrhoea, syphilis, and trichomoniasis.

These statistics indicate that STIs impose a huge burden worldwide and that large numbers of people should be subjected to testing and education. Public awareness in India has been increased through the National AIDs control organization (NACO), community-based studies have shown that 6 percent or more of the adult population has contracted one or more STIs. Such activities have contributed to the rise in interest among people in sexual health, thus creating the demand for HSV testing services. With this awareness on the rise, there will be the anticipation that more people will come in seeking the test, and this will further boost the market.

Are advanced molecular diagnostic technologies boosting market growth for HSV testing?

The HSV testing market is also highly boosted by advanced molecular diagnostic technologies. These technologies, particularly the ones associated with PCR, are highly sensitive and specific and can allow accurate detection of HSV-1 and HSV-2 even at the asymptomatic stage or during latency. The idea that such diagnostics are crucial has gained more and more traction both with the Government and educational institutions that include PCR and other molecular tests in national policies and standard procedures of diagnostics.

With such advancements comes the ability to have faster and more assured results than through traditional methods that enhance patient management and clinical decision-making. There is increased efficiency due to the availability of multiplex testing kits with which a variety of HSV can be detected and distinguished simultaneously. The technologies, which are being taken on by hospitals and diagnostic laboratories, will improve the accuracy of testing and lower turnaround time.

Does the high cost of advanced HSV testing limit adoption in developing regions?

The cost of advanced HSV testing is one of the major constraints to market growth, especially in developing regions. Molecular diagnostic tests like PCR and multiplex tests cost a lot because of the use of expensive equipment and reagents, and skilled personnel. A lot of healthcare units in low- and middle-income countries cannot even cover these intensive tests with their financial means, which reduces their availability to patients. There is also a considerable out-of-pocket cost to persons, which is prohibitive in ensuring regular screening and early diagnosis.

This barrier in terms of cost usually prompts healthcare providers to use less accurate or slower methods to test data, which comes as a cost to the effectiveness of the testing. Resource-constrained settings have limited funds to provide sexual health programs, which contributes to the problem. As a result, the use of advanced technologies in the diagnostics of HSV is not evenly distributed in different regions of the world, although there is increasing evidence of its awareness and necessity in the timely detection of HSV.

Can telemedicine integration enhance the convenience and reach of HSV testing solutions?

Integration within telemedicine represents a major opportunity for the HSV testing market, providing better convenience and accessibility. The patients will have the chance to discuss their cases with medics, get advice on how and where to test by means of telehealth platforms, and they can pre-order at-home HSV test kits. The strategy minimizes requirements to visit a physician in person, hence making the testing more readily available to persons in remote or underserved locations. The Telemedicine ensures secure sharing of results and follow-ups, which will provide timely medical advice and management of the patient.

The process of testing can also be greatly improved with integration with mobile applications and digital interfaces, which will help boost the adoption rate. Telehealth-enabled HSV testing has the potential to reach a wider audience, as sexual health becomes an increasingly acceptable concept. Combined, this electronic transition offers a flexible platform that increases market penetration and produces growth.

Is developing low-cost rapid tests creating opportunities in emerging markets?

The development of HSV low cost rapid HSV testing is generating enormous opportunities in the HSV Testing Market, particularly in the emerging regions. Access to HSV diagnostics can be extended to all communities and regions without any advanced healthcare infrastructure because cost-effective and readily available tests can be easily used. The last-minute consequences of these rapid tests are beneficial, as they allow detecting the virus early and treating it accordingly before the infection can spread.

Reducing costs lowers the cost burden both to a healthcare system and to an individual patient, spurring regular screening and prevention practices. Emerging economies, where there is an increasing awareness about sexually transmitted diseases, are a huge market where such accessible methods are required. Also, inexpensive rapid tests can be implemented at community health programs and at-home testing initiatives to expand their use and access. This is a market-enhancing trend as it will allow market penetration and enhance population health outcomes.

What are the key market segments in the HSV Testing industry?

Based on the product type, the HSV Testing Market is classified into HSV-1, HSV-2, and Others. The HSV-2 segment is the largest in the testing industry of the HSV. HSV-2 is the main cause of genital herpes infections, which are clinically more important because they are recurrent and affect sexual health. HSV-2 testing is important in routine screening, prenatal care, and in diagnosing symptomatic patients since an early diagnosis allows the prevention of infection and outbreaks.

Other medical facilities, such as hospitals and diagnostic laboratories, also focus on HSV-2 testing due to its high rates and the risk of complications in newborn babies when a woman is infected with this virus during pregnancy. Although HSV-1 is ubiquitous and frequently associated with oral herpes, HSV-2 contributes to a greater volume of clinical testing as a consequence of its clinical implications. The relative access to sensitive testing techniques, including serological and PCR testing, has compounded the emphasis on HSV-2. In general, the HSV-2 segment is the most commercially relevant, which is also attributable to the increasing interest in early diagnosis and patient management.

Based on the Test Type, the HSV Testing Market is classified into Serological Tests, PCR Tests, Rapid Diagnostic Tests, and Culture-Based Tests. Serological Tests are the dominant segment of the HSV testing market. The sensitivity of such tests lies in detecting antibodies that the body used to develop in response to infection with HSV and can hence be used to determine past and mixed infections. Their popularity is attributed to their high reliability, convenience of administration, and appropriateness of administration in high-throughput screening programs.

Serological assays are being used widely in hospitals and diagnostic laboratories because of their capabilities in offering accurate findings using small amounts of samples. They have also been favored in common health checkups and prenatal screening, where early detection is vital to the management of the patients. Serological tests remain the most popular because of their accessibility and the track record it has developed over time, and despite the current popularity of PCR and rapid diagnostic tools, both due to their speed and accuracy, they lack their track record. Constant increase in sensitivity and specificity of similar tests has only served to strengthen its superiority. In totality, there is a robust presence of the serological segment in the market owing to its extensive diagnostic functionality and clinical usefulness.

Which regions are leading the HSV Testing market, and why?

The North American HSV testing market is a renowned industry sector in the healthcare diagnostics market, due to the enhanced awareness of the diseases and adequate health care infrastructure, as well as the high prevalence of the diseases. The market consists of a variety of testing procedures, including serological assays, PCR-based diagnostics, and rapid assays to identify infections in cases of both HSV-1 and HSV-2. The leading end-users remain hospitals, according to the importance of medical establishments in diagnosing and treating HSV cases.

The use of combined HSV-1/HSV-2 tests is rising because of the complete diagnostic properties of these tests. Substantial breakthroughs in molecular diagnostics have increased the specificity and sensitivity of testing. There is also the at-home testing solution, which has become popular due to its convenience and privacy benefits to the patient. The integration of digital health platforms and telemedicine is empowering accessibility and patient engagement. The market is growing at a steady pace, backed by the invention, creation of awareness, and necessity of good quality and time aspect of diagnosis.

The Asia Pacific HSV testing market is growing at a high rate as more people are becoming aware of sexually transmitted infections, the development of new technologies in diagnosing these conditions, and increased sexual health screening across the populace. China, India, Japan, and South Korea are among the countries that are experiencing increased demand in terms of HSV testing services owing to better infection rates and access to healthcare. A wide variety of test methods, such as serological and PCR-based diagnostics and rapid antigen tests, and a variety of healthcare settings, including the hospital and diagnostic laboratories, and home care, put demands on the market as well.

P.O.C. testing is becoming popular in the region, which provides fast and convenient tests, especially in underserved regions and remote areas. Nevertheless, several obstacles should be mentioned, such as the lack of awareness of the health condition in rural areas, the financial aspects of the gap in access to healthcare, and the necessity of affordable diagnostic methods. These challenges are opportunities to increase the market and innovate. Governments and healthcare institutions are gradually targeting their attention on public health interventions to make the population aware of HSV prevention and the necessity of early diagnosis.   

What does the competitive landscape of the HSV Testing market look like?

The HSV testing market is highly competitive, with it having established diagnostics majors and emerging players. The predominant companies with the best offerings are Abbott Laboratories, Thermo Fisher Scientific, and F. Hoffmann-La Roche Ltd., which manufacture various kinds of diagnostic products, serological tests, PCR tests, and rapid test kits. These market leaders have good brand awareness, a large distribution network, and huge investments in research and development.

Competitors like Newfoundland Diagnostics are making gains by specializing in at-home testing products and responding to the demand in the market for convenient/discreet testing. Regional forces also affect the market, as North America possesses a significant share of the market thanks to the developed healthcare infrastructure and elevated levels of awareness. Conversely, the Asia Pacific is booming in terms of growth, which is attributable to the spread of access to healthcare and the rising rate of infections. The HSV testing market is generally developing, with a mix of those who have made their presence felt, along with new players who have been coming in, thus bringing diversification and growth in diagnostic opportunities.

HSV Testing Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the HSV Testing industry?

• In June 2025, the U.S. FDA classified HSV nucleic acid-based CNS assays as Class II, providing a clear regulatory pathway for developers.
• In July 2025, Innovative Molecules GmbH completed Phase 1b enrollment for IM-250, advancing its development for recurrent genital herpes treatment.

Report Coverage:

By Type

• HSV-1
• HSV-2
• Others

By Test Type

• Serological Tests
• PCR Tests
• Rapid Diagnostic Tests
• Culture-Based Tests

By Sample Type

• Blood Samples
• Serum Samples
• Swab Samples

By Applications

• Routine Screening
• Diagnosis of Active Infection
• Prenatal Testing
• Epidemiological Studies
• Others

By End-User

• Hospitals and Clinics
• Diagnostic Laboratories
• At-Home Testing
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• BD (Becton, Dickinson and Company)
• Bio-Rad Laboratories, Inc.
• bioMérieux SA
• DiaSorin S.p.A.
• Hologic, Inc.
• Cepheid
• QuidelOrtho Corporation
• Siemens Healthineers
• PerkinElmer
• Agilent Technologies
• Ortho Clinical Diagnostics
• Grifols

Frequently Asked Questions (FAQs)